Lapatinib Intermediate CAS 231278-84-5 Purity > 98.0% (HPLC)
Tshuaj npe | 5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde |
Synonyms | Lapatinib Intermediate 3;5-[4-[[3-Chloro-4-[(3-Fluorophenyl)methoxy]phenyl]amino]-6-Quinazolinyl]-2-Furancarboxaldehyde;5-[4-((3-Chloro-4-((3-Fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl]-2-Furaldehyde |
CAS Nr | 231278-84-5 |
Tshuag xwm txheej | Nyob rau hauv Tshuag, ntau lawm Scale mus txog Tons |
Molecular Formula | C26H17ClFN3O3 |
Molecular Luj | 473.90 ib |
Melting Point | 225.0 txog 235.0 ℃ |
Qhov ntom | 1.407 ± 0.06 g / cm3 |
Refractive Index | 1.694 ib |
COA & MSDS | Muaj |
Keeb kwm | Shanghai, Suav |
Hom | Ruifu Tshuaj |
Yam khoom | Specifications |
Qhov tshwm sim | Pale Yellow to Yellow Solid Powder |
Purity / Analysis Method | > 98.0% (HPLC) |
Melting Point | 225.0 ~ 235.0 ℃ |
Poob rau ziab | <1.00% |
Residue ntawm Ignition | <0.50% |
Tag nrho cov impurities | <2.00% |
Heavy Metals (raws li Pb) | <20 ppm |
Test Standard | Enterprise Standard |
Kev siv | API API (CAS 388082-77-7) |
Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj
Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde (CAS: 231278-84-5) yog ib qho nruab nrab ntawm API (CAS 388082-77-7) ).(CAS 388082-77-7) yog ib qho tshuaj tsom rau mob qog noj ntshav tsim los ntawm British GlaxoSmithKline Co. Nws yog ib qho tyrosine kinase inhibitor uas tuaj yeem cuam tshuam cov tyrosine kinase kev ua ntawm tib neeg epidermal kev loj hlob receptors 1 thiab 2 (ErbB1, ErbB2).Nws tuaj yeem ua haujlwm tshwj xeeb hauv ntau txoj hauv kev, kom ntseeg tau tias cov qog nqaij hlav cancer mis tsis tuaj yeem txais cov cim kev loj hlob.Nws inhibits intracellular EGFR (ErbB-1) thiab HER2 (ErbB-2) ATP chaw, tiv thaiv qog cell phosphorylation thiab ua kom muaj zog, thaiv cov kev cai qis los ntawm homogeneity thiab heterogeneity ntawm EGFR (ErbB-1) thiab HER2 (ErbB-1) dimerization.